Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81
Haemonetics Corporation (NYSE:HAE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to 81 from $99 while maintaining an Outperform rating. The firm updated its model following the company’s Q3 results and lowered the estimate ...